Your browser is no longer supported. Please, upgrade your browser.
Settings
AKBA Akebia Therapeutics, Inc. daily Stock Chart
AKBA [NASD]
Akebia Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.62 Insider Own0.50% Shs Outstand48.32M Perf Week-1.18%
Market Cap846.57M Forward P/E- EPS next Y-1.74 Insider Trans422.84% Shs Float35.75M Perf Month16.49%
Income-140.20M PEG- EPS next Q-0.50 Inst Own61.50% Short Float6.12% Perf Quarter6.25%
Sales50.90M P/S16.63 EPS this Y-56.90% Inst Trans27.91% Short Ratio4.77 Perf Half Y92.53%
Book/sh1.40 P/B12.51 EPS next Y35.10% ROA-52.60% Target Price19.67 Perf Year87.78%
Cash/sh6.65 P/C2.64 EPS next 5Y- ROE-218.70% 52W Range7.16 - 17.79 Perf YTD68.30%
Dividend- P/FCF10.53 EPS past 5Y-29.20% ROI-200.40% 52W High-1.52% Beta0.97
Dividend %- Quick Ratio1.80 Sales past 5Y- Gross Margin- 52W Low144.69% ATR0.53
Employees90 Current Ratio1.80 Sales Q/Q- Oper. Margin- RSI (14)66.40 Volatility3.08% 3.29%
OptionableYes Debt/Eq0.00 EPS Q/Q44.30% Profit Margin- Rel Volume0.56 Prev Close17.70
ShortableYes LT Debt/Eq0.00 EarningsAug 14 AMC Payout- Avg Volume458.45K Price17.52
Recom2.20 SMA204.14% SMA5016.08% SMA20044.91% Volume254,483 Change-1.02%
Sep-15-17Initiated RBC Capital Mkts Sector Perform $17
Jul-10-17Reiterated H.C. Wainwright Buy $25 → $24
Apr-27-17Reiterated Needham Buy $14 → $18
Apr-27-17Reiterated H.C. Wainwright Buy $18 → $21
Dec-27-16Reiterated H.C. Wainwright Buy $17 → $18
Dec-20-16Reiterated JMP Securities Mkt Outperform $16 → $19
Nov-15-16Initiated Aegis Capital Buy
Sep-29-16Initiated Brean Capital Buy
Mar-16-16Reiterated Needham Buy $18 → $14
Jan-21-16Initiated Credit Suisse Neutral
Dec-15-15Reiterated Needham Buy $14 → $18
Dec-15-15Reiterated H.C. Wainwright Buy $24 → $25
Dec-07-15Initiated H.C. Wainwright Buy $24
Sep-09-15Upgrade Morgan Stanley Equal-Weight → Overweight
Aug-13-15Initiated Morgan Stanley Equal-Weight $10
Jun-22-15Initiated JMP Securities Mkt Outperform $24
May-14-15Initiated Brean Capital Buy $18
May-11-15Initiated Needham Buy $14
Apr-14-14Initiated UBS Buy $28
Sep-08-17 08:35AM  Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Sep-07-17 01:24PM  BioMarin Presents Interim Data on BMN 250 from Phase I/II Zacks
Sep-05-17 08:42AM  Why Akebia Therapeutics (AKBA) Could Be Positioned for a Surge Zacks
08:30AM  Akebia to Present at Upcoming Investor Conferences Business Wire
Aug-23-17 07:10AM  Featured Company News - ContraVir Announces Issuance of New US Patent for Expansion of Cyclophilin Inhibitor Program ACCESSWIRE
Aug-14-17 08:27AM  Akebia Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : AKBA-US : August 14, 2017 Capital Cube
Aug-08-17 11:04PM  Akebia Therapeutics reports 2Q loss Associated Press
04:05PM  Akebia Announces Second Quarter 2017 Financial Results Business Wire
Aug-04-17 04:05PM  Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Jul-24-17 01:53PM  ETFs with exposure to Akebia Therapeutics, Inc. : July 24, 2017 Capital Cube
Jul-20-17 05:08PM  Ex-Akebia employee faces losing bail in insider trading case Reuters
Jul-14-17 12:41PM  ETFs with exposure to Akebia Therapeutics, Inc. : July 14, 2017 Capital Cube
Jul-12-17 03:09PM  Akebia Therapeutics, Inc. Value Analysis (NASDAQ:AKBA) : July 12, 2017 Capital Cube
Jul-11-17 09:15AM  Akebia Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : AKBA-US : July 11, 2017 Capital Cube
Jul-06-17 07:00AM  Akebia Announces Closing of Public Offering of Common Stock and Exercise of Option by Underwriters Business Wire
Jun-29-17 09:26AM  Biotech Movers: Akebia Shares Down After Pricing Stock Offering TheStreet.com
Jun-28-17 10:46PM  Akebia Announces Pricing of Public Offering of Common Stock Business Wire
04:15PM  Akebia Therapeutics Announces Proposed Public Offering of Common Stock Business Wire
Jun-20-17 07:00AM  Akebia Therapeutics to Host Analyst and Investor Day on June 27, 2017 Business Wire
Jun-05-17 08:00AM  Akebia Prevails in Two Additional European Patent Disputes Business Wire
May-25-17 08:30AM  Akebia Therapeutics Names Rita Jain, M.D. as Chief Medical Officer Business Wire
May-24-17 07:00AM  Akebia Initiates Phase 2 FO2RWARD Study of Vadadustat in Dialysis Patients with Anemia Related to Chronic Kidney Disease Hyporesponsive to Treatment with Erythropoiesis-Stimulating Agents Business Wire
May-17-17 06:59PM  Four Stocks Moving On Both News And The Charts Forbes
08:00AM  Today's Research Reports on Stocks to Watch: Akebia Therapeutics and xG Technology Accesswire
May-16-17 12:02PM  Why Akebia Therapeutics Stock Is Skyrocketing Today Motley Fool +16.36%
09:34AM  Biotech Movers: Akebia, Editas, Novavax TheStreet.com
01:01AM  Vifor Pharma and Akebia Announce Exclusive License Agreement to Provide Vadadustat to Fresenius Medical Care in the U.S. Upon FDA Approval GlobeNewswire
May-15-17 04:05PM  Akebia Secures Exclusive Access to U.S. Dialysis Patients With Vifor-Fresenius Pact TheStreet.com
04:05PM  Akebia and Vifor Pharma Announce Exclusive License Agreement to Provide Vadadustat to Fresenius Medical Care in the U.S. Upon FDA Approval Business Wire
May-09-17 06:28PM  Akebia Therapeutics reports 1Q loss Associated Press
04:05PM  Akebia Announces First Quarter 2017 Financial Results Business Wire
May-04-17 04:05PM  Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Apr-28-17 04:34PM  Akebia Therapeutics, Inc. Value Analysis (NASDAQ:AKBA) : April 28, 2017 Capital Cube
08:20AM  Akebia Therapeutics (AKBA) Shows Strength: Stock Up 5.8% Zacks
Apr-27-17 12:05PM  4 Things To Know About Akebia's New Vadadustat Collaboration With Otsuka Pharma Benzinga +5.84%
08:33AM  Akebia Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : AKBA-US : April 27, 2017 Capital Cube
Apr-26-17 05:45PM  Why Akebia Therapeutics Shares Soared 33.4% Today Motley Fool +33.40%
10:59AM  Akebia Surges but is Still Undervalued, Making Takeover a Potential Remedy TheStreet.com
09:27AM  Biotech Movers: Akebia Soars on Expanded Partnership With Otsuka TheStreet.com
Apr-25-17 07:00PM  Akebia expands anemia drug pact with Japanese firm, lifting shares American City Business Journals
05:41PM  Akebia shares jump on expanded anemia drug deal with Otsuka MarketWatch
04:25PM  Akebia Expands Anemia Pill Partnership to Include Europe, China Rights TheStreet.com
04:05PM  Akebia and Otsuka Expand Relationship with Collaboration to Develop and Commercialise Vadadustat in Europe, China and Other Territories Business Wire
04:01PM  Akebia and Otsuka Expand Relationship with Collaboration to Develop and Commercialize Vadadustat in Europe, China and Other Territories Business Wire
Apr-07-17 07:30AM  Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Mar-29-17 04:05PM  Akebia to Present at the 16th Annual Needham Healthcare Conference Business Wire
Mar-28-17 07:00AM  Akebia Announces Publication of Phase 2a Results for Vadadustat in Patients with Anemia Related to Chronic Kidney Disease Business Wire
Mar-10-17 01:04PM  AKEBIA THERAPEUTICS, INC. Financials
Mar-07-17 02:34PM  Why Akebia Therapeutics Inc. Tanked Today Motley Fool -12.78%
02:34PM  Why Akebia Therapeutics Inc. Tanked Today at Motley Fool
09:28AM  Biotech Premarket Movers: Innoviva, Akebia, Geron
Mar-06-17 11:34PM  Edited Transcript of AKBA earnings conference call or presentation 6-Mar-17 9:30pm GMT Thomson Reuters StreetEvents
05:54PM  Akebia Therapeutics reports 4Q loss Associated Press
04:08PM  AKEBIA THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
04:05PM  Akebia Announces Fourth Quarter and Full-Year 2016 Financial Results Business Wire
07:07AM  Q4 2016 Akebia Therapeutics Inc Earnings Release - After Market Close
Mar-01-17 08:30AM  Akebia to Host Conference Call on March 6th to Discuss Full-Year 2016 Financial Results and Corporate Highlights Business Wire
Feb-22-17 03:53PM  3 Biotech Stocks You May Be Overlooking Motley Fool
03:53PM  3 Biotech Stocks You May Be Overlooking at Motley Fool
Feb-15-17 08:40AM  KalVista Pharmaceuticals (KALV) in Focus: Stock Jumps 6% Zacks
Feb-14-17 09:30AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia Therapeutics Zacks
Feb-13-17 09:14AM  Forget Gilead, Buy These 5 Biotech Stocks Instead
08:15AM  Advanced Accelerator (AAAP) Catches Eye: Stock Jumps 5.4%
07:07AM  AKEBIA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financ
07:00AM  Akebia Licenses Portfolio of Novel HIF Compounds from Johnson & Johnson Innovation Business Wire
Feb-08-17 12:10PM  Merrimack Pharmaceuticals employee arrested, charged with insider trading at bizjournals.com
Feb-03-17 08:30AM  Concordia International (CXRX) Looks Good: Stock Jumps 11.4%
08:30AM  Akebia to Present at the 19th BIO CEO & Investor Conference Business Wire
Jan-18-17 08:31AM  Why Akebia Therapeutics (AKBA) Could Be Positioned for a Surge
Jan-11-17 10:51AM  Moving Average Crossover Alert: Akebia (AKBA)
Jan-05-17 12:56PM  Better Buy: Organovo Holdings, Inc. vs. Akebia Therapeutics, Inc. at Motley Fool
Jan-03-17 08:35AM  Cempra (CEMP) Worth a Look: Stock Jumps 7.7% in Session
Jan-01-17 03:07PM  3 Under-the-Radar Biotech Stocks to Watch in 2017 at Motley Fool
Dec-30-16 08:44AM  Earnings Estimates Moving Higher for Akebia Therapeutics (AKBA): Time to Buy?
Dec-29-16 04:24AM  Akebia Therapeutics (AKBA) Shares March Higher, Can It Continue?
Dec-28-16 10:08AM  Top Ranked Momentum Stocks to Buy for December 28th
Dec-22-16 07:21AM  Christmas Came Early for These Biotech Stocks at Motley Fool
Dec-21-16 01:28PM  Akebia Therapeutics Inc (AKBA) Sells Partial US Rights For Vadadustat To Otsuka at Insider Monkey
08:45AM  Akebia Therapeutics (AKBA) in Focus: Stock Jumps 19.4%
Dec-20-16 02:19PM  Why Akebia Therapeutics Inc Stock Zoomed Higher Today at Motley Fool +19.40%
11:35AM  Akebia Therapeutics Jumps on License and Collaboration Deal
07:06AM  AKEBIA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
07:01AM  Akebia Funds Late-Stage Studies of Anemia Pill With Partnership for U.S. Commercial Rights
07:00AM  Akebia and Otsuka Pharmaceutical Announce Collaboration to Develop and Commercialize Vadadustat in the U.S. Business Wire
Dec-17-16 04:27PM  Is Akebia Therapeutics Inc (AKBA) A Good Stock To Buy? at Insider Monkey
Dec-14-16 04:07PM  AKEBIA THERAPEUTICS, INC. Files SEC form 8-K/A, Change in Directors or Principal Officers
Dec-12-16 07:00AM  Akebia Prevails in Additional European Patent Dispute Business Wire
Dec-07-16 07:07AM  SHAREHOLDER ALERT: Sarraf Gentile LLP Announces Securities Class Action Lawsuit Against Akebia Therapeutics, Inc. Marketwired
Dec-02-16 04:05PM  Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Nov-28-16 02:28PM  Akebia Therapeutics, Inc. :AKBA-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016
Nov-15-16 07:43AM  Coverage initiated on Akebia Therapeutics by Aegis Capital
Nov-09-16 04:05PM  AKEBIA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report +10.64%
04:04PM  Akebia Therapeutics reports 3Q loss
04:01PM  Akebia Announces Third Quarter 2016 Financial Results Business Wire
Oct-31-16 04:05PM  Akebia to Present at the Credit Suisse 25th Annual Healthcare Conference Business Wire
Oct-17-16 07:00AM  Akebia Announces Presentations at the Upcoming American Society of Nephrology Kidney Week 2016 Annual Meeting Business Wire
Sep-29-16 09:05AM  Akebia Price Target Lowered, Still A Buy At Brean
Sep-26-16 07:00AM  Akebia Announces Publication Highlighting Potential Benefits of HIF Treatments for Patients with Renal Anemia Business Wire
Sep-20-16 05:17PM  AKEBIA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Sep-19-16 08:30AM  Akebia Announces Publication of Phase 2b Data for Vadadustat in Non-Dialysis Patients with Anemia Related to Chronic Kidney Disease Business Wire
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product candidates that include AKB-6899 for the treatment of anemia; and AKB-5169, a preclinical compound for the treatment for inflammatory bowel disease. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, Europe, China, and internationally, as well as with Mitsubishi Tanabe Pharma Corporation for the development and commercialization to vadadustat in Japan and other Asian countries. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dahan MichelSVP, Chief Business OfficerAug 15Sale15.005,00075,000102,224Aug 17 04:06 PM
Satter Muneer ADirectorJul 05Buy14.501,034,48214,999,9893,037,042Jul 11 04:14 PM
Hadas Nicole R.SVP, General Counsel, Sec.Jul 03Sale14.261,55422,156109,607Jul 06 12:24 PM
Dahan MichelSVP, Chief Business OfficerJul 03Sale14.261,39919,947107,224Jul 06 12:25 PM
Nash DuaneDirectorJul 03Sale14.2799014,12723,687Jul 06 12:23 PM
Hadas Nicole R.SVP, General Counsel, Sec.Apr 03Sale9.181,55614,280109,856Apr 04 04:01 PM
Nash DuaneDirectorApr 03Sale9.209919,11924,677Apr 04 04:01 PM
Dahan MichelSVP, Chief Business OfficerApr 03Sale9.181,40112,858108,623Apr 04 04:01 PM
Butler John P.CEO and PresidentJan 19Option Exercise0.4720,0009,400373,480Jan 23 04:10 PM
Nash DuaneDirectorJan 03Sale10.461,98020,71125,668Jan 03 04:02 PM
Dahan MichelSVP, Chief Business OfficerJan 01Sale10.491,62917,08970,524Jan 03 04:02 PM
Hadas Nicole R.SVP, General Counsel, Sec.Jan 01Sale10.491,81018,98882,912Jan 03 04:01 PM
Nash DuaneDirectorOct 03Sale8.961,98117,74627,648Oct 04 04:12 PM
Hadas Nicole R.SVP, General Counsel, Sec.Oct 01Sale8.951,55613,93483,915Oct 04 04:12 PM
Dahan MichelSVP, Chief Business OfficerOct 01Sale8.951,40112,54672,153Oct 04 04:12 PM